ADOCIA is managed by a committee made up of three members: Olivier Soula, CEO; Valérie Danaguezian, CFO; Gérard Soula, President.
PhD, MBA – President
Gerard Soula has an MBA from IAE (Aix Marseille) and a Ph.D. in organic chemistry and graduated from IAE. He founded Flamel Technologies (in 1990), a biotech company specialized in Drug Delivery and listed on Nasdaq. He was the CEO and Director of Research until June 2005. When he left, Flamel had 250 employees, $100M cash in bank and a market capitalization of $500M. Flamel Technologies’ success is based on the performances of its platforms, Micropump and Medusa. Furthermore, Gérard Soula has a strong track record in negotiating license agreements in innovating technologies with big pharma groups (Novo Nordisk, Bristol Myers Squibb, GlaxoSmithKline etc). He is co-author of more than 120 patents.
Chief Financial Officer
Valérie Danaguezian worked for 4 years as an external auditor at Calan Ramolino & Associés (Deloitte & Touche). In 1991, she joined Sanofi Pasteur where she was in charge of the financial consolidation of the Group; she was then promoted to Director of R&D controlling. In 2003, she joined Flamel Technologies as Financial Director, a position she held for 3 years. She joined Adocia in 2006 as Financial Director and member of Adocia Committee management.
PhD, MBA – CEO
Olivier Soula has a Ph.D. in polymer science and graduated from ENSIC Mulhouse, and has an MBA from IAE, Lyon. He worked for 8 years at Flamel Technologies as Director of the Nanotechnologies department. He led the development of Medusa, a prolonged release platform of therapeutic proteins and successfully conducted clinical trials for three of those projects. Olivier is co-author of nearly 40 patents relating to protein delivery. He has worked for 16 years on insulin formulation.